Literature DB >> 1838680

MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex.

F R Sharp1, P Jasper, J Hall, L Noble, S M Sagar.   

Abstract

MK-801 and ketamine are noncompetitive N-methyl-D-aspartate (NMDA) receptor blockers that decrease brain injury in animal models of focal and global ischemia. Recent reports, however, suggested that MK-801 itself can damage neurons. Here we show that MK-801 (0.1 to 5.0 mg/kg) and ketamine (40 to 100 mg/kg) typically induce heat shock protein HSP72 mainly in layer 3 neurons of the posterior cingulate and retrosplenial cortex of the rat. These HSP72-immunoreactive neurons contain abnormal cytoplasmic vacuoles visualized by electron microscopy. The HSP72 immunoreactivity is maximal at 24 hours with 1.0-mg/kg doses of MK-801 and disappears by 2 weeks. Based on these data, we propose: (1) MK-801 and ketamine injure selected neurons, which express HSP72 in response to that injury. (2) Since HSP72 is induced for 1 to 2 weeks, the prolonged psychological side effects of MK-801, ketamine, phencyclidine, and related drugs could be related to this injury. (3) The neuroprotective effect of MK-801 is probably not related to HSP72 induction. (4) HSP72 immunocytochemistry is useful for studying nonlethal neuronal injury from a wide variety of brain insults.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1838680     DOI: 10.1002/ana.410300609

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

1.  Expression profiling to understand actions of NMDA/glutamate receptor antagonists in rat brain.

Authors:  Petri Törönen; Marcus Storvik; Anni-Maija Lindén; Outi Kontkane; Markéta Marvanová; Merja Lakso; Eero Castrén; Garry Wong
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond.

Authors:  R M Kostrzewa
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

4.  Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents.

Authors:  A M Lindén; J Väisänen; M Lakso; H Nawa; G Wong; E Castrén
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

5.  Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Authors:  Sargo Aalto; Jouni Ihalainen; Jussi Hirvonen; Jaana Kajander; Harry Scheinin; Heikki Tanila; Kjell Någren; Harry Vilkman; Lars L Gustafsson; Erkka Syvälahti; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 6.  Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Authors:  Joseph T Coyle; Alo Basu; Michael Benneyworth; Darrick Balu; Glenn Konopaske
Journal:  Handb Exp Pharmacol       Date:  2012

7.  Neuronal vacuole formation in the rat posterior cingulate/retrosplenial cortex after treatment with the N-methyl-D-aspartate (NMDA) antagonist MK-801 (dizocilpine maleate).

Authors:  A S Fix; J W Horn; L L Truex; R A Smith; E Gomez
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 8.  Blockade of glutamate excitotoxicity and its clinical applications.

Authors:  K Hirose; P H Chan
Journal:  Neurochem Res       Date:  1993-04       Impact factor: 3.996

Review 9.  Excitotoxicity, energy metabolism and neurodegeneration.

Authors:  A C Ludolph; M Riepe; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.

Authors:  R J Hargreaves; M Rigby; D Smith; R G Hill
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.